Throughout the world, chronic non-communicable diseases exert a tremendous economic and social burden. The recent World Health Organization Status Report on Non-communicable Diseases (NCDs) estimates that 63% or 36 million of the 57 million deaths that occurred globally in 2008 were attributable to NCDs , primarily cardiovascular diseases, cancers, diabetes and chronic lung diseases.
Most Recent Posts
Each year, Ernst & Young publishes a report about the global biotechnology sector. In this year's report, which they recently released, they comment about the notable fact that it has been 25 years since they began the report - how far a once-nascent field has evolved in that short amount of time!
It's a hefty read, but they included a really worthwhile two-page chart that details the state of the sector.
An op-ed in the Cleveland Plain Dealer by William Burga, a former president of the Ohio AFL-CIO, is a good reminder that support for patent reform - which I've written about in the past - is important not just to biopharmaceutical research companies, but to all sectors that are stimulated by the patent system.
Summer is finally upon us, and though at times it almost seems too steamy to venture outside, it serves as a good reminder about the importance of taking care of your skin.
Yesterday, PhRMA President and CEO John J. Castellani spoke at the Personalized Medicine Coalition's 7th annual State of Personalized Medicine Luncheon. He spoke about the many challenges confronting the biopharmaceutical sector as it increasingly turns its attention to personalized medicine, but also about the promise that the field offers.
The Association of Nurses in AIDS Care was founded in 1987 with a mission of promoting the individual and collective professional development of nurses involved in the delivery of healthcare to patients with HIV/AIDS. ANAC is a member-driven, chapter-based organization of over 2,500 nurses united to advocate for their HIV patients and advance HIV/AIDS research and standards of HIV care. In its goals is the abiding commitment to the prevention of further HIV infection.
Ezra Klein's column in yesterday's Washington Post on the Medicare prescription drug benefit discusses why costs in Part D have come in beneath expectations. He makes some fair points. But Ezra overlooks the program's unique design that is helping to keep costs far below initial projections and coverage affordable for beneficiaries.
We're focused this week on the past 30 years of HIV/AIDS and how the disease - and with it, the world - has changed in those three decades.
But what does 30 years really mean?
To me, it's nearly a lifetime. To early patients who have survived and are with us today, it may feel like a miracle.
To help put it into context, some of my colleagues made an incredibly moving brief video about the timeline of AIDS research and advances.
David Mixner has been a long-time human rights and HIV/AIDS patient advocate. He took a few moments to speak with me about how the disease has changed from a patient perspective over the last 30 years, and it was a truly human reminder of how much our progress really means.
AstraZeneca CEO David Brennan, in his role as President of the International Federation of Pharmaceutical Manufacturers and Associations, gave the
Unsurprisingly, coverage of the AIDS 30th anniversary has been heating up. On Friday on NPR's All Things Considered, University of Alabama-Birmingham's Dr. Michael Saag spoke about spending his entire career treating AIDS, as he began his residency in 1981.
Grady, my partner in blogging, is enviably vacationing in the south of France, so you'll be hearing even more from me in the next 10 days or so. I don't know who is luckiest: Grady, me or you...
Anyway, two topics will be front and center throughout the week: the progress we've made since HIV/AIDS was first formally recognized 30 years ago and the tremendous promise of personalized medicine. As you'll see, there are many common threads in these separate but very much entwined story lines.